A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: A Hoosier Oncology Group trial

Patrick Loehrer, S. Turner, P. Kubilis, Siu Hui, J. Correa, R. Ansari, D. Stephens, R. Woodburn, S. Meyer

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

From May 1984 through December 1986, 141 patients with metastatic adenocarcinoma of the colon or rectum were entered on this Hoosier Oncology Group (HOG) trial evaluating the role of cisplatin in systemic therapy. Patients were stratified by the presence or absence of hepatic metastases and by performance status, and were subsequently randomized to receive fluorouracil (5-FU) (15 mg/kg/wk) alone or the same dose of 5-FU plus cisplatin (60 mg/m2 every 3 weeks). The total duration of treatment was six cycles (18 weeks). In 132 fully evaluable patients the objective response rates were 19% for 5-FU and 22% for 5-FU plus cisplatin. Statistically, the median survival times of 40 and 39 weeks were not significantly different (P = .62). However, the median duration of remission (MDR) was superior (P = .05) for 5-FU alone. This study fails to confirm clinically significant synergy of 5-FU plus cisplatin in the treatment of metastatic colorectal cancer.

Original languageEnglish
Pages (from-to)642-648
Number of pages7
JournalJournal of Clinical Oncology
Volume6
Issue number4
StatePublished - 1988

Fingerprint

Fluorouracil
Cisplatin
Colorectal Neoplasms
Therapeutics
Rectum
Colon
Adenocarcinoma
Neoplasm Metastasis
Survival
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer : A Hoosier Oncology Group trial. / Loehrer, Patrick; Turner, S.; Kubilis, P.; Hui, Siu; Correa, J.; Ansari, R.; Stephens, D.; Woodburn, R.; Meyer, S.

In: Journal of Clinical Oncology, Vol. 6, No. 4, 1988, p. 642-648.

Research output: Contribution to journalArticle

@article{c76e26e79b194bde9c13fbe52e3f1254,
title = "A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: A Hoosier Oncology Group trial",
abstract = "From May 1984 through December 1986, 141 patients with metastatic adenocarcinoma of the colon or rectum were entered on this Hoosier Oncology Group (HOG) trial evaluating the role of cisplatin in systemic therapy. Patients were stratified by the presence or absence of hepatic metastases and by performance status, and were subsequently randomized to receive fluorouracil (5-FU) (15 mg/kg/wk) alone or the same dose of 5-FU plus cisplatin (60 mg/m2 every 3 weeks). The total duration of treatment was six cycles (18 weeks). In 132 fully evaluable patients the objective response rates were 19{\%} for 5-FU and 22{\%} for 5-FU plus cisplatin. Statistically, the median survival times of 40 and 39 weeks were not significantly different (P = .62). However, the median duration of remission (MDR) was superior (P = .05) for 5-FU alone. This study fails to confirm clinically significant synergy of 5-FU plus cisplatin in the treatment of metastatic colorectal cancer.",
author = "Patrick Loehrer and S. Turner and P. Kubilis and Siu Hui and J. Correa and R. Ansari and D. Stephens and R. Woodburn and S. Meyer",
year = "1988",
language = "English",
volume = "6",
pages = "642--648",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer

T2 - A Hoosier Oncology Group trial

AU - Loehrer, Patrick

AU - Turner, S.

AU - Kubilis, P.

AU - Hui, Siu

AU - Correa, J.

AU - Ansari, R.

AU - Stephens, D.

AU - Woodburn, R.

AU - Meyer, S.

PY - 1988

Y1 - 1988

N2 - From May 1984 through December 1986, 141 patients with metastatic adenocarcinoma of the colon or rectum were entered on this Hoosier Oncology Group (HOG) trial evaluating the role of cisplatin in systemic therapy. Patients were stratified by the presence or absence of hepatic metastases and by performance status, and were subsequently randomized to receive fluorouracil (5-FU) (15 mg/kg/wk) alone or the same dose of 5-FU plus cisplatin (60 mg/m2 every 3 weeks). The total duration of treatment was six cycles (18 weeks). In 132 fully evaluable patients the objective response rates were 19% for 5-FU and 22% for 5-FU plus cisplatin. Statistically, the median survival times of 40 and 39 weeks were not significantly different (P = .62). However, the median duration of remission (MDR) was superior (P = .05) for 5-FU alone. This study fails to confirm clinically significant synergy of 5-FU plus cisplatin in the treatment of metastatic colorectal cancer.

AB - From May 1984 through December 1986, 141 patients with metastatic adenocarcinoma of the colon or rectum were entered on this Hoosier Oncology Group (HOG) trial evaluating the role of cisplatin in systemic therapy. Patients were stratified by the presence or absence of hepatic metastases and by performance status, and were subsequently randomized to receive fluorouracil (5-FU) (15 mg/kg/wk) alone or the same dose of 5-FU plus cisplatin (60 mg/m2 every 3 weeks). The total duration of treatment was six cycles (18 weeks). In 132 fully evaluable patients the objective response rates were 19% for 5-FU and 22% for 5-FU plus cisplatin. Statistically, the median survival times of 40 and 39 weeks were not significantly different (P = .62). However, the median duration of remission (MDR) was superior (P = .05) for 5-FU alone. This study fails to confirm clinically significant synergy of 5-FU plus cisplatin in the treatment of metastatic colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023896783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023896783&partnerID=8YFLogxK

M3 - Article

C2 - 3282033

AN - SCOPUS:0023896783

VL - 6

SP - 642

EP - 648

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -